ClinicalTrials.gg

Program

sintilimab

Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.

Furthest: phase 3, since May 7, 201740 company-led studies, 13 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics295 open or runningphase 3since May 7, 2017Oct 8, 2016Mar 25, 2030phase 3 · NCT07917468
HUTCHMED31 open or runningphase 3since Aug 16, 2022Mar 27, 2019Jan 8, 2029phase 3 · NCT06584032
Beijing Aosaikang Pharmaceutical11 open or runningphase 2since Nov 21, 2022Nov 21, 2022none ahead
Chipscreen Biosciences11 open or runningphase 3since Jun 28, 2024Jun 28, 2024May 31, 2028phase 3 · NCT06497985
CSPC Pharmaceutical Group11 open or runningphase 2since Jul 30, 2026Jul 30, 2026Sep 30, 2029phase 2 · NCT07761286
Sichuan Luzhou Buchang Biopharmaceutical11 open or runningphase 1since Jan 2, 2025Jan 2, 2025none ahead
Simcere Pharmaceutical Group10 open or runningphase 1since Jan 29, 2023Jan 29, 2023none ahead
Suzhou Zelgen Biopharmaceuticals11 open or runningphase 2since Aug 14, 2024Aug 14, 2024none ahead
TaiRx11 open or runningphase 2since Mar 31, 2026Mar 31, 2026Dec 31, 2027phase 2 · NCT07521852
TJ Biopharma11 open or runningphase 2since May 21, 2025May 21, 2025none ahead

Also a collaborator on its studies: fortrea.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since Oct 8, 2016.

  1. Oct 5, 2022Phase 2 study in MelanomaInnovent Biologics · NCT05572463 · United States, Australia, France and more
  2. Nov 21, 2022Beijing Aosaikang Pharmaceutical's first study: phase 2 study in Stomach NeoplasmsNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT05632939 · 62 enrolled · China
  3. Jan 29, 2023Simcere Pharmaceutical Group's first study: phase 1 study in Advanced Solid TumorsNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT05718219 · 49 enrolled · China
  4. Apr 17, 2023Phase 2 study in Non-squamous Non-small-cell Lung CancerInnovent Biologics · NCT05849246 · 4 enrolled · China
  5. Jun 28, 2024Chipscreen Biosciences's first study: phase 3 study in Colorectal NeoplasmsNew to Chipscreen BiosciencesChipscreen Biosciences · NCT06497985 · 430 planned · China
  6. Aug 14, 2024Suzhou Zelgen Biopharmaceuticals's first study: phase 2 study in Carcinoma, HepatocellularNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT06558227 · 90 planned · China
  7. Aug 21, 2024Phase 3 study in Endometrial NeoplasmsHUTCHMED · NCT06584032 · 412 planned · China
  8. Jan 2, 2025Sichuan Luzhou Buchang Biopharmaceutical's first study: phase 1 study in Stomach NeoplasmsNew to Sichuan Luzhou Buchang BiopharmaceuticalSichuan Luzhou Buchang Biopharmaceutical · NCT06773312 · 80 planned · China
  9. May 21, 2025TJ Biopharma's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to TJ BiopharmaTJ Biopharma · NCT07005336 · 150 enrolled · China
  10. Mar 16, 2026Phase 2 study in CLDN18.2 PositiveInnovent Biologics · NCT07483567 · 90 planned · China
  11. Mar 31, 2026TaiRx's first study: phase 2 study in Carcinoma, HepatocellularNew to TaiRxTaiRx · NCT07521852 · 40 planned · China
  12. Jun 4, 2026Phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaInnovent Biologics · NCT07643623 · 720 planned · China
  13. Jul 30, 2026CSPC Pharmaceutical Group's first study: phase 2 study in Carcinoma, HepatocellularNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07761286 · 288 planned · China
  14. Oct 19, 2026Phase 3 study in Locally Advanced Rectal CancerInnovent Biologics · NCT07917468 · 500 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularTaiRx · NCT07521852
  2. May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985
  3. Jan 8, 2029Primary completion: phase 3 study in Endometrial NeoplasmsHUTCHMED · NCT06584032
  4. Sep 30, 2029Primary completion: phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 40 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07917468Locally Advanced Rectal Cancer · China3Not yet recruitingInnovent BiologicsMar 25, 2030500
NCT07761286Carcinoma, Hepatocellular · China2Not yet recruitingCSPC Pharmaceutical GroupSep 30, 2029288
NCT07643623Resectable Gastric/Gastroesophageal Junction Adenocarcinoma · China3RecruitingInnovent BiologicsDec 31, 2031720
NCT07521852Carcinoma, Hepatocellular · China2RecruitingTaiRxDec 31, 202740
NCT07483567CLDN18.2 Positive · China2RecruitingInnovent BiologicsJun 30, 203090
NCT07005336Carcinoma, Non-Small-Cell Lung · China2Active, not recruitingTJ BiopharmaAug 30, 2026150
NCT06773312Stomach Neoplasms · China1RecruitingSichuan Luzhou Buchang BiopharmaceuticalOct 202680
NCT06584032Endometrial Neoplasms · China3RecruitingHUTCHMEDJan 8, 2029412
NCT06558227Carcinoma, Hepatocellular · China2RecruitingSuzhou Zelgen BiopharmaceuticalsSep 202690
NCT06497985Colorectal Neoplasms · China3RecruitingChipscreen BiosciencesMay 31, 2028430
NCT05849246Non-squamous Non-small-cell Lung Cancer · China2TerminatedInnovent BiologicsNov 30, 20234
NCT05718219Advanced Solid Tumors · China1TerminatedSimcere Pharmaceutical GroupApr 30, 202549
NCT05632939Stomach Neoplasms · China2Active, not recruitingBeijing Aosaikang PharmaceuticalOct 31, 202562
NCT05572463Melanoma · United States, Australia, France and more2WithdrawnInnovent BiologicsJun 30, 20270
NCT05522231Advanced Renal Cell Carcinoma · China3CompletedHUTCHMEDAug 28, 2026265
NCT05337267Healthy Male Subjects · China1CompletedInnovent BiologicsMay 24, 2023117
NCT05280626Lymphoma, Large B-Cell, Diffuse2Not yet recruitingInnovent BiologicsDec 31, 2025100
NCT05119998Solid Tumor · China1CompletedInnovent BiologicsJul 27, 202348
NCT05116462Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingInnovent BiologicsSep 30, 2026506
NCT05039658DLBCL · China1UNKNOWNInnovent BiologicsJul 12, 202250
NCT04675983Gastric Adenocarcinoma · China3TerminatedInnovent BiologicsFeb 12, 202336
NCT04427774Advanced or Metastatic Solid Tumors · China1TerminatedInnovent BiologicsFeb 8, 20218
NCT04401813Advanced Hepatocellular Carcinoma · China1CompletedInnovent BiologicsJun 21, 202497
NCT04353830Advanced Malignancies · China1CompletedInnovent BiologicsMay 11, 202234
NCT04277663Acral Melanoma That Has Been Removed by Surgery · China3TerminatedInnovent BiologicsFeb 28, 2023136
NCT04258111Colorectal Neoplasms · China2TerminatedInnovent BiologicsOct 26, 20204
NCT04177290Carcinoma, Non-Small-Cell Lung · China1CompletedInnovent BiologicsFeb 28, 202148
NCT04085185Advanced Malignancies · China1UNKNOWNInnovent BiologicsDec 15, 2023268
NCT04044222Classic Hodgkin's Lymphoma · China3UNKNOWNInnovent BiologicsJul 30, 2023240
NCT03903705Advanced Solid Tumor · China2CompletedHUTCHMEDNov 15, 2023348
NCT03802240Non-Squamous Non-Small Cell Lung Cancer · China3CompletedInnovent BiologicsJul 31, 2021492
NCT03745170Stomach Neoplasms · China3CompletedInnovent BiologicsJun 20, 2021650
NCT03748134Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more3CompletedInnovent BiologicsSep 9, 2021746
NCT03629925Squamous NSCLC · China3CompletedInnovent BiologicsMar 25, 2020357
NCT03607539Lung Neoplasms · China3CompletedInnovent BiologicsNov 15, 2019397
NCT03568539Advanced/Metastatic Solid Malignancies · United States1CompletedInnovent BiologicsNov 9, 202039
NCT03228836Effect of Drugs · China2CompletedInnovent BiologicsFeb 28, 202028
NCT03150875Carcinoma, Non-Small-Cell Lung · China3CompletedInnovent BiologicsFeb 22, 2023290
NCT03116152Esophageal Squamous Cell Carcinoma · China2CompletedInnovent BiologicsOct 2, 2019190
NCT02937116Neoplasms · China1CompletedInnovent BiologicsSep 30, 2020233

How it is read

Names in the registry

  • “Sintilimab”, 15 entries
  • “IBI308”, 5 entries
  • “IBI939+ Sintilimab”, 2 entries
  • “IBI110+ Sintilimab”, 2 entries
  • “fruquintinib+sintilimab”, 1 entry

Codes read as this program: IBI308.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.